MOLIQIO is a liquid biopsy solution based on NGS (Next-Generation Sequencing), designed for Ultra-sensitive ctDNA detection and the accurate monitoring of cancer patients.

Developed by IntegraGen in partnership with Twist Bioscience, this technology allows ctDNA detection with exceptional sensitivity (LOD down to 0.003% %), adapted to the needs of the’precision oncology and from minimal residual disease (MRD) monitoring.

The solution relies on:

• east custom panels from WES (Whole Exome Sequencing),
• a optimized library preparation,
• a Advanced bioinformatics analysis with UMI duplex technology,

guaranteeing a maximum specificity and a fast turnaround.

Compliant with standards CLIA/CAP, MOLIQIO generates a Reliable and actionable clinical report, facilitating the therapeutic follow-up, the early detection of relapses and the Personalized oncology decision-making.

👉Watch our Webinar Developing an Integrated MRD Assay to Transform Oncology.